Funding for this research was provided by:
Institut National du Cancer (PHRC-K-2017-026)
Received: 15 April 2020
Accepted: 17 May 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: The study protocol has been approved by the ANSM (Agence National de Sureté du Médicament, N°: MEDAECNAT-2018-10-00037) and the CPP (Comité de Protection des Personnes, CPP77–18, N°22.214.171.124606) in December 2018. All screened eligible patients that accept to participate will have to sign informed consent form before inclusion in the sudy.
: not applicable.
: AB:Speaker fee: Takeda, Merck-Serono, Abbvie, Roche, Amgen, Janssen-Cilag.Invitation to scientific meeting: Biom’up, Roche, Win’up surgical system, Intuitive surgical.JBB:Employment, (Merck Serono), honoraria (Amgen, Bayer, Celgene,Merck Serono, Roche, Sanofi/Aventis, Servier/Pfizer), consulting or advisory role (Amgen, Bayer, Merck Serono, Servier/Pfizer), non-financial disclosure (Amgen, Merck, Serono, Roche);EV: None.MK: None.PA:honoraria (Roche, Amgen, Bayer, Servier, Lilly, Merck Serono), consulting or advisory role (Roche, Merck Serono, Servier), non-financial disclosure (Roche, Merck Serono, Bayer).CS: None.JHL:Honoraria from Vifor Pharma (2012), Takeda (2018), and MDStart (2018) and being invited to an international medical congress by Sanofi (2015), Eumedica (2015), Biomup (2019).Consultency for Safeheal.DW: None.CM: None.FH: None.SB:Speaker fee: Merck Serono, Roche, Amgen, Nestlé, Takeda, Abbvie, Biom’up, Sanofi, Servier, Win’up.Scientific board/Consultency: Amgen, Biom’up, Win’up.